Search for content, post, videos

Health Canada OKs Weight Drug

Health Canada has approved the new drug submission for Novo Nordisk’s Saxenda® (liraglutide), the first once-daily human glucagon-like peptide-1 (GLP-1) analogue for the treatment of chronic weight management.

Saxenda® is an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in obese adults and overweight adults with at least one weight-related condition, such as hypertension, type 2 diabetes and who have failed a previous weight management intervention.

The Saxenda® approval in Canada follows the Committee for Medicinal Products for Human Use (CHMP) positive opinion under the European Medicines Agency (EMA) on Jan. 22, 2015 and the US Food and Drug Administration (FDA) approval of Saxenda® Dec. 23, 2014.

SOURCE Novo Nordisk Canada Inc.